Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F22%3A00076482" target="_blank" >RIV/00159816:_____/22:00076482 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/22:00076482 RIV/00064203:_____/22:10444556 RIV/00216208:11130/22:10444556 RIV/00216224:14110/22:00126164

Výsledek na webu

<a href="https://ascopubs.org/doi/pdf/10.1200/PO.21.00525?role=tab" target="_blank" >https://ascopubs.org/doi/pdf/10.1200/PO.21.00525?role=tab</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1200/PO.21.00525" target="_blank" >10.1200/PO.21.00525</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing

Popis výsledku v původním jazyce

There are about 100 new children presenting with anaplastic large cell lymphoma (ALCL) in the United States and Europe each year. Among these patients, approximately 90% harbor ALK gene rearrangements, with NPM1-ALK being the most prevalent.1 Despite the use of several different intensive chemotherapy approaches, about one third of patients will experience a relapse of the disease.2 In relapsed patients, multiple therapeutic strategies can be considered. The frequency of ALK gene rearrangements in ALCL and the success of ALK inhibitors in other cancer types3 led to early use of tyrosine kinase inhibitors (TKIs) in patients with ALK gene rearrangement-positive ALCL (ALK-positive ALCL). Crizotinib, which showed to be not only well-tolerated in the pediatric population but also to have high response rates,4 is already approved for relapsed ALCL in children and young adults.

Název v anglickém jazyce

Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing

Popis výsledku anglicky

There are about 100 new children presenting with anaplastic large cell lymphoma (ALCL) in the United States and Europe each year. Among these patients, approximately 90% harbor ALK gene rearrangements, with NPM1-ALK being the most prevalent.1 Despite the use of several different intensive chemotherapy approaches, about one third of patients will experience a relapse of the disease.2 In relapsed patients, multiple therapeutic strategies can be considered. The frequency of ALK gene rearrangements in ALCL and the success of ALK inhibitors in other cancer types3 led to early use of tyrosine kinase inhibitors (TKIs) in patients with ALK gene rearrangement-positive ALCL (ALK-positive ALCL). Crizotinib, which showed to be not only well-tolerated in the pediatric population but also to have high response rates,4 is already approved for relapsed ALCL in children and young adults.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

JCO PRECISION ONCOLOGY

ISSN

2473-4284

e-ISSN

2473-4284

Svazek periodika

6

Číslo periodika v rámci svazku

Jun

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

"e2100525"

Kód UT WoS článku

000814289300001

EID výsledku v databázi Scopus

2-s2.0-85133674157